BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34922209)

  • 21. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
    Shah RB; Magi-Galluzzi C; Han B; Zhou M
    Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
    Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
    Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strong PD-L1 expression in granulomatous prostatitis.
    Dikov D; Koleva M; Mollova A; Fakirova A
    Prostate; 2023 Sep; 83(13):1285-1289. PubMed ID: 37357498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.
    Palicelli A; Bonacini M; Croci S; Magi-Galluzzi C; Cañete-Portillo S; Chaux A; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Zanelli M; Bonasoni MP; De Marco L; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Santandrea G; Gelli MC; Tafuni A; Ragazzi M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
    Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
    Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
    Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
    Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
    Arimura K; Sekine Y; Hiroshima K; Shimizu S; Shibata N; Kondo M; Takeyama K; Tagaya E
    BMC Pulm Med; 2019 Sep; 19(1):169. PubMed ID: 31481045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic importance of PD-L1, PTEN, PHH3, and KI-67 expressions in invasive breast carcinoma.
    Imamoglu EH; Duzcu SE
    Rev Assoc Med Bras (1992); 2022; 68(12):1638-1644. PubMed ID: 36449787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
    Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.
    Morais CL; Guedes LB; Hicks J; Baras AS; De Marzo AM; Lotan TL
    Hum Pathol; 2016 Sep; 55():117-25. PubMed ID: 27189342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 Expression and CD8
    Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
    Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
    Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
    PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
    Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.